erlotinib hydrochloride has been researched along with zoledronic acid in 3 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (zoledronic acid) | Trials (zoledronic acid) | Recent Studies (post-2010) (zoledronic acid) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 4,108 | 620 | 2,610 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | zoledronic acid (IC50) |
|---|---|---|---|
| Carbonic anhydrase 12 | Homo sapiens (human) | 0.316 | |
| Geranylgeranyl pyrophosphate synthase | Homo sapiens (human) | 0.318 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.062 | |
| 72 kDa type IV collagenase | Homo sapiens (human) | 7 | |
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | 0.2144 | |
| Farnesyl diphosphate synthase | Escherichia coli K-12 | 1.1 | |
| Farnesyl pyrophosphate synthase | Leishmania donovani | 0.11 | |
| Geranylgeranyl pyrophosphate synthase | Saccharomyces cerevisiae S288C | 0.424 | |
| Carbonic anhydrase 9 | Homo sapiens (human) | 5.323 | |
| Carbonic anhydrase 14 | Homo sapiens (human) | 0.092 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, XH; Feng, CJ; Huang, CY; Liu, XK; Lu, Y; Wang, L; Wang, Y; Wang, YS; Xu, Y; Yao, WX; Yu, P; Zhou, J; Zhu, WJ | 1 |
| Niederer, R; Samalia, P; Sims, J | 1 |
| Barbai, T; Cserepes, M; Dobos, J; Hegedűs, Z; Kárpáti, A; Kenessey, I; László, V; Nelhűbel, GA; Őrfi, L; Rásó, E; Szabó, B; Szokol, B; Tóvári, J; Türk, D | 1 |
3 other study(ies) available for erlotinib hydrochloride and zoledronic acid
| Article | Year |
|---|---|
Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diphosphonates; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pamidronate; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2016 |
Drug-induced ocular inflammation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alendronate; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Brimonidine Tartrate; Diphosphonates; ErbB Receptors; Erlotinib Hydrochloride; Etanercept; Female; Humans; Imidazoles; Immune Checkpoint Inhibitors; Male; Middle Aged; Nivolumab; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Retrospective Studies; Scleritis; Uveitis, Anterior; Vemurafenib; Zoledronic Acid | 2020 |
EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Indoles; Mice; Mice, SCID; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Squamous Cell Carcinoma of Head and Neck; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2021 |